论文部分内容阅读
目的研究乳腺癌组织中人类表皮生长因子受体-3(HER-3)的表达,并分析其表达与乳腺癌临床病理及预后的关系。方法收集2006年1～10月期间大连医科大学附属第二医院行手术、术前未经放化疗、术后行内分泌治疗且资料完整的女性乳腺癌患者139例。采用免疫组织化学法检测乳腺癌组织中HER-3的表达,并从病历资料中获得组织学分级、肿瘤大小、淋巴结转移、联系方式等资料,分析HER-3表达与乳腺癌患者的临床病理特征及预后的关系。结果①HER-3在乳腺癌组织中的表达阳性率为30.2%(42/139);②HER-3表达与患者年龄无关(r=0.030,P=0.721);③HER-3表达与肿瘤的大小(r=0.176,P=0.038)、淋巴结转移(r=0.205,P=0.016)及组织学分级(r=0.197,P=0.020)呈正相关,与5年生存率呈负相关(r=-0.254,P=0.003)。结论 HER-3的检测对乳腺癌的早诊断、早治疗、用药、预后有指导意义,并有可能指导新抗肿瘤药物的研发方向。
Objective To study the expression of human epidermal growth factor receptor-3 (HER-3) in breast cancer and to analyze its relationship with the clinicopathology and prognosis of breast cancer. Methods A total of 139 female patients with breast cancer who underwent endocrine therapy after operation and without preoperative radiotherapy and chemotherapy before operation were collected from the Second Affiliated Hospital of Dalian Medical University from January to October in 2006. Immunohistochemistry was used to detect the expression of HER-3 in breast cancer tissues. Histological grade, tumor size, lymph node metastasis and contact information were also obtained from the medical records. The clinical and pathological features of HER-3 in breast cancer were analyzed And prognosis. Results ① The positive expression rate of HER-3 in breast cancer was 30.2% (42/139). ② The expression of HER-3 was not related to the age of patients (r = 0.030, P = 0.721) = 0.176, P = 0.038), lymph node metastasis (r = 0.205, P = 0.016) and histological grade (r = 0.197, P = 0.020), but negatively correlated with 5-year survival rate = 0.003). Conclusion The detection of HER-3 is of guiding significance for the early diagnosis, early treatment, medication and prognosis of breast cancer and may guide the development of new anti-tumor drugs.